Department of Otorhinolaryngology, Head and Neck Surgery, Radboud University Nijmegen Medical Center, Donders Institute for Brain, Cognition and Behavior, Nijmegen, The Netherlands.
Laryngoscope. 2011 Jul;121(7):1359-66. doi: 10.1002/lary.21763. Epub 2011 Jun 6.
OBJECTIVES/HYPOTHESIS: A prospective long-term follow-up study was conducted to evaluate the results of gamma knife radiosurgery (GKRS) for vestibular schwannoma (VS) patients. Both axial and volumetric measurements are used to determine tumor size during follow-up.
Individual prospective cohort study.
A total of 110 VS patients were referred for radiosurgery between 2002 and 2007. All patients were treated with a Leksell 4C gamma knife. There were 12.5 to 13 Gy prescribed to the isodose covering 90% of the tumor volume. The resulting marginal dose was on average 11.0 Gy (range, 9.3-12.5 Gy). Tumor size and tumor volume were determined before and after gamma knife treatment at regular intervals. The minimal follow-up period was 2 years.
There were 100 patients included in the study. Eight patients needed additional treatment after a mean follow-up period of 38 months. One patient experienced a temporary facial nerve deficit. No growth pattern could be recognized for tumor growth after GKRS. Based on the measurements of the largest extrameatal diameter, the tumor size would have decreased or remained stable in 94%. Based on volumetric measurement, the tumor size was decreased or remained stable in 79%.
High tumor control and low complication rates make GKRS a good therapy for VS. If tumor growth occurs after GKRS, a conservative management can be considered because continued tumor growth is uncertain. The extrameatal diameter on axial magnetic resonance imaging seems to be a reliable parameter of the size of a VS. Volumetry is the preferred method to assess the dimensions of a VS, although the consequences of strong volumetric increase, especially in small tumors, can be different depending on individual differences in tumor size.
目的/假设:本前瞻性长期随访研究旨在评估伽玛刀放射外科(GKRS)治疗前庭神经鞘瘤(VS)患者的结果。在随访期间,使用轴位和体积测量来确定肿瘤大小。
个体前瞻性队列研究。
2002 年至 2007 年间,共有 110 例 VS 患者被转诊行放射外科治疗。所有患者均采用 Leksell 4C 伽玛刀治疗。处方剂量为 12.5 至 13Gy,覆盖肿瘤体积的 90%。平均边缘剂量为 11.0Gy(范围为 9.3-12.5Gy)。在伽玛刀治疗前后定期测量肿瘤大小和肿瘤体积。最小随访时间为 2 年。
研究共纳入 100 例患者。8 例患者在平均 38 个月的随访后需要额外治疗。1 例患者出现暂时性面神经功能障碍。在 GKRS 后,无法识别肿瘤生长的生长模式。根据最大外耳道直径的测量,肿瘤大小缩小或稳定的比例为 94%。根据体积测量,肿瘤大小缩小或稳定的比例为 79%。
高肿瘤控制率和低并发症率使 GKRS 成为 VS 的一种较好的治疗方法。如果 GKRS 后肿瘤生长,可考虑保守治疗,因为持续的肿瘤生长是不确定的。轴位磁共振成像上的外耳道直径似乎是 VS 大小的可靠参数。尽管体积强烈增加的后果(尤其是在小肿瘤中)可能因肿瘤大小的个体差异而不同,但体积测量是评估 VS 尺寸的首选方法。